Contact Us
Drug Search Results
More Filters [+]

Ridaforolimus

Alternative Names: ridaforolimus, mk-8669, ap23573, mk8669
Latest Update: 2024-11-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: mTOR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ridaforolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Sarcoma|Bone Cancer|Soft Tissue Cancer|Osteosarcoma

Phase 2: Endometrial Cancer|Sarcoma|Oncology Unspecified|Prostate Cancer|Myeloid Leukemia|Myelodysplastic Syndrome|Lymphoma|Myelofibrosis|Breast Cancer|Liposarcoma|Leiomyosarcoma|Osteosarcoma|Non-Small-Cell Lung Cancer

Phase 1: Sarcoma|Primary Central Nervous System Lymphoma|Lymphoma|Multiple Myeloma|Oncology Solid Tumor Unspecified|Heart Cancer|Glioma|Glioblastoma|Oncology Unspecified|Liver Failure|Hepatic Insufficiency|Gliosarcoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Breast Cancer|Endometrial Cancer|Colorectal Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
IoNIR-002

N/A

Not yet recruiting

Coronary Artery Disease|Coronary Stenosis

2026-09-01

CHAMPIONSHIP

N/A

Recruiting

Peripheral Arterial Disease

2025-08-30

IonMAN

N/A

Active, not recruiting

Non-ST Elevated Myocardial Infarction|Coronary Stenosis|Coronary Disease

2024-09-30

EluNIR-005

N/A

Completed

Coronary Stenosis|Myocardial Ischemia

2021-11-02

Recent News Events

Date

Type

Title

06/11/2024

News Article

 Nimble Announces Formation of a World-Class Scientific Advisory Board

03/22/2024

PubMed

 Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review.

01/16/2024

PubMed

 Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding Risk.

01/01/2024

PubMed

 Percutaneous coronary intervention with ridaforolimus eluting-stents in small vessel coronary artery disease.

09/05/2023

News Article

 The Drug Coated Stent market size and share analysis provides a comprehensive picture of the market's projected CAGR of 12.8% from 2023 to 2030 through its analysis of market segmentation, sales volume, and share.

10/19/2022

News Article

 Drug Eluting Stent Market is estimated to be US$ 14.02 billion by 2032 with a CAGR of 6.5% during the forecast period 2032 - By PMI

07/30/2019

News Article

 North American Companion Diagnostics Devices Market 2019-2024 - Rising Demand & Awareness for Personalized Medicine & Targeted Therapy Drives Market Growth - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions